BSX analyst scorecard · Boston Scientific
95 rating actions on BSX in the last 12 months. Of 131 price targets that resolved, 3 were reached while they stood, 125 were replaced by the same firm first, and 3 fell short at their deadline. Ratings: 90% Buy-type, 10% Hold-type, 0% Sell-type. Consensus target $53, 24% above the last close.
Checked through 2026-10-29 · last close $42.65 (2026-10-29). Rebuilt every morning.
Targets reached while they stood
2.3% 3 of 131
Replaced before the deadline
95.4%
Short at the deadline
2.3%
Ratings vs XLV
0 of 19
Buy / Hold / Sell, 12 mo
90 / 10 / 0%
Consensus target
$53 +23.7%
What the Holds say: 7 Hold-type ratings on BSX in the last 12 months carried a median target +12% from the price on the day; 0% sat below it.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Outperform | 2026-07-30 | $55 | 0 | 6 | 6 | 0 of 1 |
| RBC Capital | Outperform | 2026-07-30 | $70 | 0 | 8 | 8 | 0 of 1 |
| Truist Securities | Buy | 2026-10-14 | $51 | 0 | 15 | 15 | 0 of 1 |
| Stifel | Buy | 2026-10-26 | $55 | 0 | 6 | 6 | 0 of 1 |
| Needham | Buy | 2026-10-28 | $48 | 0 | 13 | 13 | 0 of 1 |
| Citigroup | Neutral | 2026-10-05 | $48 | 0 | 9 | 9 | 0 of 1 |
| Canaccord Genuity | Buy | 2026-07-30 | $66 | 1 | 8 | 9 | 0 of 1 |
| BTIG | Buy | 2026-10-29 | $49 | 0 | 13 | 13 | 0 of 1 |
| Barclays | Equal-Weight | 2026-10-07 | $48 | 0 | 8 | 8 | 0 of 1 |
| Wolfe Research | Peer Perform | 2026-05-29 | — | — | — | 0 | — |
| Oppenheimer | Outperform | 2026-09-21 | $65 | 0 | 4 | 4 | 0 of 1 |
| Wells Fargo | Equal-Weight | 2026-10-29 | $45 | 2 | 7 | 9 | 0 of 1 |
| UBS | Buy | 2026-10-29 | $57 | 0 | 6 | 6 | 0 of 1 |
| TD Cowen | Buy | 2026-08-25 | $56 | 0 | 1 | 2 | 0 of 1 |
| Mizuho | Outperform | 2026-07-15 | $70 | 0 | 2 | 2 | — |
| Baird | Outperform | 2026-10-29 | $51 | 0 | 7 | 7 | 0 of 1 |
| Leerink Partners | Outperform | 2026-10-29 | $50 | 0 | 3 | 3 | 0 of 1 |
| Jefferies | Buy | 2026-06-24 | $67 | 0 | 1 | 1 | — |
| Goldman Sachs | Buy | 2026-04-23 | $84 | 0 | 1 | 1 | — |
| Argus Research | Hold | 2026-07-31 | — | — | — | 0 | — |
| Bank of America | Buy | 2026-05-18 | $68 | — | — | 0 | — |
| Raymond James | Outperform | 2026-03-30 | $88 | 0 | 4 | 4 | 0 of 1 |
| JPMorgan | Overweight | 2026-02-05 | $100 | 0 | 0 | 1 | 0 of 1 |
| Morgan Stanley | Overweight | 2026-02-05 | $118 | 0 | 3 | 3 | 0 of 1 |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor BSX carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-29 | Leerink Partners | Outperform | maintained | $42.65 | $50 | running to 2027-10-29 | -2.8% |
| 2026-10-29 | UBS | Buy | maintained | $42.65 | $57 | running to 2027-10-29 | -2.8% |
| 2026-10-29 | Wells Fargo | Equal-Weight | maintained | $42.65 | $45 | running to 2027-10-29 | -2.8% |
| 2026-10-29 | Baird | Outperform | maintained | $42.65 | $51 | running to 2027-10-29 | -2.8% |
| 2026-10-29 | BTIG | Buy | maintained | $42.65 | $49 | running to 2027-10-29 | -2.8% |
| 2026-10-28 | Needham | Buy | maintained | $42.43 | $48 | running to 2027-10-28 | -3.8% |
| 2026-10-26 | Stifel | Buy | maintained | $45.58 | $55 | running to 2027-10-26 | +3.8% |
| 2026-10-14 | Truist Securities | Buy | maintained | $43.00 | $51 | running to 2027-10-14 | -4.5% |
| 2026-10-07 | Barclays | Equal-Weight | initiated | $41.58 | $48 | running to 2027-10-07 | -13.0% |
| 2026-10-05 | Citigroup | Neutral | maintained | $42.40 | $48 | running to 2027-10-05 | -11.3% |
| 2026-09-24 | Wells Fargo | Equal-Weight | maintained | $44.68 | $48 | replaced 2026-10-29, new $45 | -10.4% |
| 2026-09-21 | Oppenheimer | Outperform | maintained | $43.72 | $65 | running to 2027-09-21 | -13.2% |
| 2026-09-17 | Citigroup | Buy → Neutral | downgrade | $43.55 | $50 | replaced 2026-10-05, new $48 | -13.7% |
| 2026-09-09 | BTIG | Buy | maintained | $44.96 | $56 | replaced 2026-10-29, new $49 | -10.9% |
| 2026-08-25 | TD Cowen | Buy | reiterated | $49.86 | $56 | running to 2027-08-25 | +12.7% |
| 2026-07-31 | Argus Research | Buy → Hold | downgrade | $46.73 | — | no target | +8.5% |
| 2026-07-30 | UBS | Buy | maintained | $46.00 | $67 | replaced 2026-10-29, new $57 | +7.8% |
| 2026-07-30 | Citigroup | Buy | maintained | $46.00 | $61 | replaced 2026-09-17, new $50 | +7.8% |
| 2026-07-30 | RBC Capital | Outperform | maintained | $46.00 | $70 | running to 2027-07-30 | +7.8% |
| 2026-07-30 | TD Cowen | Buy | maintained | $46.00 | $56 | running to 2027-07-30 | +7.8% |
| 2026-07-30 | Canaccord Genuity | Buy | maintained | $46.00 | $66 | running to 2027-07-30 | +7.8% |
| 2026-07-30 | Truist Securities | Buy | maintained | $46.00 | $57 | replaced 2026-10-14, new $51 | +7.8% |
| 2026-07-30 | Evercore ISI Group | Outperform | maintained | $46.00 | $55 | running to 2027-07-30 | +7.8% |
| 2026-07-30 | Wells Fargo | Equal-Weight | maintained | $46.00 | $50 | reached 2026-08-10 | +7.8% |
| 2026-07-29 | BTIG | Buy | maintained | $46.04 | $60 | replaced 2026-09-09, new $56 | +5.9% |
| 2026-07-27 | Oppenheimer | Outperform | maintained | $45.51 | $85 | replaced 2026-09-21, new $65 | +2.9% |
| 2026-07-16 | Truist Securities | Buy | maintained | $44.62 | $62 | replaced 2026-07-30, new $57 | -4.9% |
| 2026-07-15 | Mizuho | Outperform | maintained | $43.04 | $70 | running to 2027-07-15 | -8.0% |
| 2026-07-13 | RBC Capital | Outperform | maintained | $44.65 | $85 | replaced 2026-07-30, new $70 | -4.8% |
| 2026-07-08 | Needham | Buy | maintained | $44.81 | $57 | replaced 2026-10-28, new $48 | -8.0% |
| 2026-07-06 | Evercore ISI Group | Outperform | maintained | $44.60 | $65 | replaced 2026-07-30, new $55 | -8.1% |
| 2026-06-25 | Stifel | Buy | maintained | $44.20 | $65 | replaced 2026-10-26, new $55 | -23.3% |
| 2026-06-24 | Jefferies | Buy | maintained | $44.46 | $67 | running to 2027-06-24 | -23.1% |
| 2026-06-16 | BTIG | Buy | reiterated | $46.92 | $65 | replaced 2026-07-29, new $60 | -10.9% |
| 2026-06-04 | Truist Securities | Buy | maintained | $48.85 | $64 | replaced 2026-07-16, new $62 | -12.7% |
| 2026-06-03 | BTIG | Buy | maintained | $47.69 | $65 | replaced 2026-07-29, new $60 | -16.1% |
| 2026-06-01 | Canaccord Genuity | Buy | maintained | $47.98 | $70 | replaced 2026-07-30, new $66 | -15.1% |
| 2026-05-29 | Wolfe Research | Outperform → Peer Perform | downgrade | $48.31 | — | no target | -15.5% |
| 2026-05-28 | Citigroup | Buy | maintained | $49.11 | $70 | replaced 2026-07-30, new $61 | -16.0% |
| 2026-05-28 | Leerink Partners | Outperform | maintained | $49.11 | $74 | replaced 2026-10-29, new $50 | -16.0% |
| 2026-05-28 | Barclays | Overweight | maintained | $49.11 | $89 | replaced 2026-10-07, new $48 | -16.0% |
| 2026-05-28 | Wells Fargo | Overweight → Equal-Weight | downgrade | $49.11 | $55 | replaced 2026-07-30, new $50 | -16.0% |
| 2026-05-19 | Baird | Outperform | maintained | $56.81 | $75 | replaced 2026-10-29, new $51 | -11.6% |
| 2026-05-18 | Bank of America | Buy | maintained | $55.92 | $68 | running to 2027-05-18 | -12.9% |
| 2026-05-18 | Needham | Buy | reiterated | $55.92 | $77 | replaced 2026-07-08, new $57 | -12.9% |
| 2026-05-18 | BTIG | Buy | reiterated | $55.92 | $80 | replaced 2026-06-03, new $65 | -12.9% |
| 2026-04-23 | Canaccord Genuity | Buy | maintained | $65.69 | $71 | replaced 2026-06-01, new $70 | -3.6% |
| 2026-04-23 | RBC Capital | Outperform | maintained | $65.69 | $100 | replaced 2026-07-13, new $85 | -3.6% |
| 2026-04-23 | Barclays | Overweight | maintained | $65.69 | $96 | replaced 2026-05-28, new $89 | -3.6% |
| 2026-04-23 | Evercore ISI Group | Outperform | maintained | $65.69 | $78 | replaced 2026-07-06, new $65 | -3.6% |
| 2026-04-23 | Wells Fargo | Overweight | maintained | $65.69 | $75 | replaced 2026-05-28, new $55 | -3.6% |
| 2026-04-23 | Truist Securities | Buy | maintained | $65.69 | $85 | replaced 2026-06-04, new $64 | -3.6% |
| 2026-04-23 | Baird | Outperform | maintained | $65.69 | $78 | replaced 2026-05-19, new $75 | -3.6% |
| 2026-04-23 | Goldman Sachs | Buy | maintained | $65.69 | $84 | running to 2027-04-23 | -3.6% |
| 2026-04-23 | Needham | Buy | maintained | $65.69 | $77 | replaced 2026-07-08, new $57 | -3.6% |
| 2026-04-22 | Jefferies | Buy | maintained | $64.87 | $100 | replaced 2026-06-24, new $67 | -6.7% |
| 2026-04-22 | Barclays | Overweight | maintained | $64.87 | $100 | replaced 2026-04-23, new $96 | -6.7% |
| 2026-04-22 | BTIG | Buy | maintained | $64.87 | $80 | replaced 2026-06-03, new $65 | -6.7% |
| 2026-04-21 | Stifel | Buy | maintained | $59.52 | $85 | replaced 2026-06-25, new $65 | -14.3% |
| 2026-04-15 | Truist Securities | Buy | maintained | $64.61 | $90 | replaced 2026-04-23, new $85 | -7.4% |
| 2026-04-13 | Mizuho | Outperform | maintained | $63.18 | $90 | replaced 2026-07-15, new $70 | -8.6% |
| 2026-04-07 | Citigroup | Buy | maintained | $61.86 | $87 | replaced 2026-05-28, new $70 | -13.3% |
| 2026-04-06 | Evercore ISI Group | Outperform | maintained | $62.59 | $80 | replaced 2026-04-23, new $78 | -12.3% |
| 2026-03-30 | RBC Capital | Outperform | reiterated | $62.93 | $115 | replaced 2026-04-23, new $100 | -18.1% |
| 2026-03-30 | Raymond James | Strong Buy → Outperform | downgrade | $62.93 | $88 | running to 2027-03-30 | -18.1% |
| 2026-03-30 | Needham | Buy | reiterated | $62.93 | $97 | replaced 2026-04-23, new $77 | -18.1% |
| 2026-03-27 | Goldman Sachs | Buy | maintained | $69.17 | $93 | replaced 2026-04-23, new $84 | -5.9% |
| 2026-03-20 | Stifel | Buy | maintained | $69.48 | $90 | replaced 2026-04-21, new $85 | -8.9% |
| 2026-03-20 | Needham | Buy | reiterated | $69.48 | $97 | replaced 2026-04-23, new $77 | -8.9% |
| 2026-03-18 | Truist Securities | Buy | maintained | $71.28 | $92 | replaced 2026-04-15, new $90 | -4.6% |
| 2026-03-17 | UBS | Buy | maintained | $71.20 | $105 | replaced 2026-07-30, new $67 | -4.7% |
| 2026-03-11 | Citigroup | Buy | maintained | $69.63 | $94 | replaced 2026-04-07, new $87 | -6.1% |
| 2026-02-17 | Canaccord Genuity | Buy | maintained | $76.29 | $109 | replaced 2026-04-23, new $71 | -13.4% |
| 2026-02-09 | BTIG | Buy | reiterated | $74.12 | $110 | replaced 2026-04-22, new $80 | -24.1% |
| 2026-02-05 | Canaccord Genuity | Buy | maintained | $77.64 | $112 | replaced 2026-02-17, new $109 | -20.6% |
| 2026-02-05 | Citigroup | Buy | maintained | $77.64 | $102 | replaced 2026-03-11, new $94 | -20.6% |
| 2026-02-05 | JPMorgan | Overweight | maintained | $77.64 | $100 | running to 2027-02-05 | -20.6% |
| 2026-02-05 | TD Cowen | Buy | maintained | $77.64 | $100 | replaced 2026-07-30, new $56 | -20.6% |
| 2026-02-05 | UBS | Buy | maintained | $77.64 | $120 | replaced 2026-03-17, new $105 | -20.6% |
| 2026-02-05 | RBC Capital | Outperform | maintained | $77.64 | $115 | replaced 2026-04-23, new $100 | -20.6% |
| 2026-02-05 | Evercore ISI Group | Outperform | maintained | $77.64 | $96 | replaced 2026-04-06, new $80 | -20.6% |
| 2026-02-05 | Wells Fargo | Overweight | maintained | $77.64 | $94 | replaced 2026-04-23, new $75 | -20.6% |
| 2026-02-05 | Morgan Stanley | Overweight | maintained | $77.64 | $118 | running to 2027-08-05 | -20.6% |
| 2026-02-05 | Stifel | Buy | maintained | $77.64 | $110 | replaced 2026-03-20, new $90 | -20.6% |
| 2026-02-05 | Baird | Outperform | maintained | $77.64 | $101 | replaced 2026-04-23, new $78 | -20.6% |
| 2026-02-05 | Mizuho | Outperform | maintained | $77.64 | $115 | replaced 2026-04-13, new $90 | -20.6% |
| 2026-02-05 | Truist Securities | Buy | maintained | $77.64 | $95 | replaced 2026-03-18, new $92 | -20.6% |
| 2026-02-05 | Needham | Buy | maintained | $77.64 | $97 | replaced 2026-04-23, new $77 | -20.6% |
| 2026-02-04 | BTIG | Buy | maintained | $75.50 | $110 | replaced 2026-04-22, new $80 | -20.9% |
| 2026-02-03 | Barclays | Overweight | maintained | $91.62 | $124 | replaced 2026-04-22, new $100 | -3.3% |
| 2026-01-16 | Oppenheimer | Outperform | maintained | $88.07 | $100 | replaced 2026-07-27, new $85 | -6.8% |
| 2025-12-18 | Truist Securities | Buy | maintained | $96.11 | $120 | replaced 2026-02-05, new $95 | -3.1% |
| 2025-12-17 | Canaccord Genuity | Buy | maintained | $94.48 | $131 | replaced 2026-02-05, new $112 | -7.2% |
| 2025-12-17 | RBC Capital | Outperform | maintained | $94.48 | $130 | replaced 2026-02-05, new $115 | -7.2% |
| 2025-11-21 | BTIG | Buy | reiterated | $96.88 | $132 | replaced 2026-02-04, new $110 | — |
Also in Medical Devices
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.